Advertisement

Topics

OxyPharma AB Company Profile

21:12 EST 9th December 2018 | BioPortfolio

OxyPharma's lead compound B-220 has its origin in anti-viral research conducted by Professor Jan Bergman between 1971 and 1975. In the following years and financed by Kabi – a Swedish pharmaceutical company Professor Bergman synthesized the substance. Its anti-viral properties were confirmed in collaboration with the Bacteriological Laboratory of Sweden (SBL). Professor Bergman continued his research with funding from Mr. Leif Lundblad and in the second half of the 1990's, B-220 also proved effective in early stage tumor processes (induced tumor promotion model – inflammatory response) and in the preservation of organs for transplantation. In 1998, based upon results from inflammatory models, studies were initiated to investigate the effect of B-220 in autoimmune disease/inflammatory models for RA, MS and inflammatory bowel disease (IBD). The compound showed promising results, leading to the incorporation of OxyPharma in 2002. A development plan was established, Mr. Ulf Björklund was appointed CEO and OxyPharma secured new funding from Mr. Lundblad through LLD Nybohov Invest.
During 2003 new and more potent analogues of B-220 were identified, resulting in the selection of a first candidate drug (CD) – Rob 803 – for the treatment of RA in early 2004 and a second CD – Rob 895 – for the treatment of MS in early 2005.

Location

Box 47041
Stockholm
S-100 74
Sweden

Contact

Phone: 46 (0)8 726 17 02
Fax: 46 (0)8 18 28 03
Email: info@oxypharma.com,


News Articles [0 Results]

None

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

OxyPharma AB

OxyPharma's lead compound B-220 has its origin in anti-viral research conducted by Professor Jan Bergman between 1971 and 1975. In the following years and financed by Kabi – a Swedish pharmaceutical...

More Information about "OxyPharma AB" on BioPortfolio

We have published hundreds of OxyPharma AB news stories on BioPortfolio along with dozens of OxyPharma AB Clinical Trials and PubMed Articles about OxyPharma AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of OxyPharma AB Companies in our database. You can also find out about relevant OxyPharma AB Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...


Corporate Database Quicklinks



Searches Linking to this Company Record